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with higher risk, but low participation rates, active case-
detection of CT-infections in “high-prevalence-area’s”
needs a concerted approach of different providers and
community organisations, both in secondary as in pri-
mary prevention. The pharmacist can contribute if proper
liaison is made with primary care providers and/or public
health services for (partner-)treatment, counseling, and
comprehensive sexual health care.
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OBJECTIVE: The UK is a low endemic area for hepati-
tis B virus. Nevertheless, the National Health Service
(NHS) burden of managing the disease and its long term
sequelae is thought to be great. Understanding the extent
of this cost is needed to estimate the budget impact of
adopting therapies that avoid morbidity and mortality.
The purpose of this study is to estimate the resources and
costs associated with major health states of chronic
hepatitis B (CHB). METHODS: Annual health care
resource use was estimated by a panel of expert hepatol-
ogists for patients with chronic active hepatitis B (CAHB),
compensated and decompensated cirrhosis (including
ascites, bacterial peritonitis, variceal haemorrhage and
hepatic encephalopathy), and hepatocellular carcinoma.
Liver transplantation costs were obtained from published
sources and unit costs from NHS-relevant sources.
RESULTS: In the UK 39% of CHB patients receive antivi-
ral therapy. The estimated annual cost is £2503 for
CAHB and £2631 for compensated cirrhosis managed
with antivirals. For patients without antivirals (61%),
annual costs are £547 (CAHB) and £745 (compensated
cirrhosis). Estimated annual cost for decompensated cir-
rhosis is £5842 using a distribution across the possible
manifestations of the disease. Hepatocellular carcinoma
is £6167 annually with less than 25% of patients receiv-
ing chemotherapy. Liver transplantation costs over
£31,000 for the transplantation and £10,700 in the ﬁrst
year post transplant. CONCLUSIONS: The direct
medical costs of CHB are substantial. Slowing or stop-
ping disease progression could reduce the morbidity and
mortality burden on patients and the cost burden for the
NHS.
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OBJECTIVES: To illustrate how value of information
analyses can be used to inform the efﬁcient design of
future research using an updated cost-effectiveness model
of Zanamivir, Oseltamivir and Amantadine versus normal
treatment for persons with inﬂuenza-like-illness (ILI).
METHODS: Systematic review and meta-analysis of evi-
dence relating to the effectiveness in terms of length of
illness, complication rate and adverse event proﬁle for all
three antiviral treatments was used to inform a proba-
bilistic decision model. The incremental cost per QALY
was estimated and Monte Carlo simulation used to 
generate a cost-effectiveness acceptability curve. The
expected value of perfect information (EVPI) was calcu-
lated. Partial EVPI for each of the uncertain parameters
in the model was calculated using a two-level simulation
approach. This same approach was used to calculate the
expected value of sample information (EVSI) for a
number of different research designs. RESULTS: For
healthy adults the incremental cost per QALY of Aman-
tadine compared to no treatment is approximately £13k.
The ICER for Oseltamivir compared to Amantadine is
approximately £42k. Oseltamivir dominates Zanamivir.
However, these estimates are extremely uncertain, as
reﬂected in the cost effectiveness acceptability curve.
Value of information analyses indicate ﬁrstly, the value of
that uncertainty within the model and secondly, the most
efﬁcient design for future research aimed at reducing that
uncertainty. CONCLUSIONS: This paper illustrates the
application of recent advances in value of information
methods to the policy relevant issue of inﬂuenza treat-
ments. It indicates that improved knowledge of the pro-
portion of individuals that actually have inﬂuenza and the
QALY values associated with inﬂuenza are two variables
of particular value for future research.
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OBJECTIVES: Although pertussis is thought of most
often as a disease of childhood, it can occur in all ages.
It has been reported that pertussis in adolescents and
adults is on the rise in some Western countries. The goal
of this analysis was to determine the age distribution of
pertussis cases in hospitals in Germany, as well the length
of stay (LOS) and related costs per stay. METHODS:
Hospital discharge data by age group for pertussis cases
(ICD-9 codes: 033.0–033.9) admitted in 1999, and 2002
per diem hospital costs were obtained from the Federal
Statistical Bureau in Germany. These data were used to
develop LOS and inpatient hospital costs by age group
for a pertussis-related hospitalization. Cost estimates are
reported in €2002. RESULTS: Of the 1118 pertussis cases
identiﬁed, 52% were female. Ages ranged from infant to
75+ years. Those <1 year comprised 65% of admissions;
9% were between 1–5 years; 19% were between 6–15
years; 2% were aged 16–25 and 5% were 26 years and
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older (adults). The mean length of stay was 10 days for
all cases with a mean cost per stay estimated at €3259.
Costs increased to €3816 for those <1 year based on a
mean LOS of 11.5 days. On average, those in the 6–15
year age group had the lowest LOS and cost per stay (6.5
days; €2157) and adults had the highest (11.9 days;
€3965). CONCLUSIONS: While most pertussis cases can
be managed in an outpatient setting, the need for hospi-
talization does occur across all age groups in Germany.
When hospitalization is required, a considerable expense
is incurred. Thus, the cost of hospitalization should be
factored into any economic analysis or decision-making
process examining the beneﬁts of vaccination to prevent
the occurrence of this infectious disease.
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Introduction: Inﬂuenza (IZ) is a highly contagious acute
respiratory disease with self-limiting duration, represent-
ing serious health risks for the elderly and those with
chronic diseases. Vaccination is effective, but the most
vulnerable population remains at risk of IZ. New, drugs
entered the market, able to reduce IZ symptoms by 1.5
°V2 days when taken within 48h of symptom onset. We
investigated the WTP for these drugs under the constraint
of information and prescription. METHOD: Population:
Health professionals, patients with chronic diseases 
and young healthy adults. Willingness to pay (WTP) was
asked through closed ended questions, using a payment
card system with increasing and decreasing bidding
ranges. Questionnaires contained 3 scenarios including 2
levels of information and were randomly allocated. 1rst
scenario informed about IZ and asked WTP for no IZ
risk, the 2nd WTP for the drugs, under time and ofﬁce
visit constraint, 3rd scenario addressed WTP for drugs 
if obtainable over the counter (OTC). RESULTS: We
obtained 1594 answers, 59% female 41% male, evenly
distributed for information, starting point and insurance.
For scenario 2, 36% were unwilling to give anything,
while only 22% answered nothing with the option of
having the drug OTC, 41% were even willing to give
more than 80CHF. WTP decreased signiﬁcantly with age.
Insurance had no inﬂuence on WTP and health profes-
sionals had a signiﬁcantly lower WTP than others.
Bidding ranges had no inﬂuence, neither did the level of
information. Participants who had been vaccinated
against inﬂuenza last year were willing to give more.
CONCLUSION: We completed successfully the ﬁrst large
randomized WTP study in Health Care. Respondents
valued independent decision-making, favouring the 3rd
scenario Preferences of participants were much lower
than the drugs market price (CHF 80). Further large WTP
studies need to be undertaken to conﬁrm the WTP
approach in Health Care.
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OBJECTIVES: The aim of study to assess the costs and
cost distribution of pulmonary tuberculosis in Ukraine
from the perspective of public health care in Ukraine.
METHODS: The direct medical costs, doctor consulta-
tions, laboratory and diagnostic tests, and hospitaliza-
tions were identiﬁed and calculated. Indirect costs due to
lost productivity were also included. RESULTS: The data
collected from 8867 patients in West regional pulmonary
centre (sity Lviv) for 2000–2002 were analysed. The
average cost per pulmonary tuberculosis patient per year
was calculated at 835 UAH (€Euro = 6.1 UAH). The dis-
ribution of total costs is as follows: pharmacological
treatment (42.5%), laborabory and diagnostic tests
(8,2%), doctors’ consultation (10.5%), hospitalization
(26.4%) and productivity loss (12.4%). Indirect costs of
pulmonary tuberculosis in Ukraine were much lower,
because a social structure of patients on Ukraine has
allowed to detect, that persons who were come back from
places of an inference—10–20%, the alcogolics—
20–50%, the immigrants—5–10%, persons not having 
of normal housing conditions and living in hostels—
10–15%. Theoretically the total burden of pulmonary
tuberculosis on society per year amounts 28.1 million
UAH (€4.6 million). CONCLUSIONS: Pulmonary tuber-
culosis represents an important economic burden for the
Ukrainian population. An optimal allocation of expendi-
ture for pharmacological treatment and hospitalization
may contribute to a signiﬁcant reduction of the total cost
of pulmonary tuberculosis in Ukraine.
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OBJECTIVES: Although efﬁcacy of alternative antibiotic
dosing regimes may be the same, compliance may vary
thus affecting treatment effectiveness. The objective of
this study was to assess the efﬁciency of once-daily 
clarithromycin (CL OD) versus conventional twice-daily
generic clarithromycin (CL BD), in patients with tonsil-
